Editorial support, including development and formatting of the figures, was provided by Sophie Walton, MSc, CMPP, of Apollo, OPEN Health, funded by Novo Nordisk in accordance with Good Publication Practice guidelines
Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, et al
The lab may need additional time due to holidays, confirmation/repeat testing, etc
The FDA declared the semaglutide shortage resolved in February 2025, but compounded semaglutide remains legal through 503A pharmacies when there is a documented medical need [3]
[17] Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been observed with incretin-based therapies